Roluperidone is seeking an indication for monotherapy in negative symptoms associated with schizophrenia. Roluperidone appears to be on track to be first-to-market in this indication.
Phase 2 data was promising and phase 3 aims to mirror it.
Risks to investment include a historically difficult indication in achieving clinical success, 2021 original patent expiration, and future competition.
While Minerva’s story is interesting, additional key developments will be required to earn a “buy” recommendation.